drugset / Trial / NCT04280692
Controlled Human Malaria Infection Transmission Model - Phase A
Phase 1/2
Suspended
44 enrolled
University of Oxford
KEMRI-Wellcome Trust Collaborative Research Program · collabKenya Medical Research Institute · collabSanaria Inc. · collab
RandomizedSequentialOpen-labelBasic science
Summary
This is to develop a model to test the efficacy of vaccines and/or drugs designed to block transmission of malaria to mosquitoes and to identify the targets of transmission-blocking immunity to malaria.
Timeline
- Start
- 2022-08-22
- Primary completion
- 2025-12
- Completion
- 2026-08
Outcome
Outcome not reported
Stopped: “Study halted prematurely due to US FDA clinical hold on PfSPZ Challenge”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | piperaquine | Small molecule | 480 mg | — |
| Subject | pyrimethamine | Small molecule | 25 mg | — |
| Subject | sulfadoxine | Small molecule | 500 mg | — |
| Background | Artemether | Small molecule | 20 mg | — |
| Background | Primaquine | Small molecule | 0.25 mg/kg | — |
| Background | lumefantrine | Small molecule | 120 mg | — |